Mutant Listeria Bacteria for Interferon-β Production Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Interferon-β stability in solutions is limited by degradation mechanisms such as aggregation and deamidation, restricting its clinical utility in treating diseases like cancer and viral infections.
Innovation Solution
Mutant Listeria bacteria with mutations in transcription regulator genes or multidrug resistance transporter genes are used to modulate interferon-β production in macrophages, providing a stable and effective method for interferon-β modulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If interferon-β is administered in purified form, then therapeutic efficacy is improved, but stability is worsened due to aggregation and deamidation
Solution Approach 1:
The patent uses Listeria bacteria as an intermediary delivery system to produce and release interferon-β in vivo, avoiding the stability issues of purified interferon-β in solution. The bacterial host provides a stable environment for interferon-β production and controlled release, preventing aggregation and deamidation that occur in purified forms.
Solution Approach 2:
The patent replaces the mechanical/administrative system of purified protein administration with a biological production system using Listeria bacteria. This substitution allows interferon-β to be produced and delivered in a stable biological context rather than as an unstable purified protein solution.
2Stability of the object's composition
If mutant Listeria bacteria are used to modulate interferon-β production, then stability is improved, but device complexity is worsened
Solution Approach 1:
The Listeria bacteria serve multiple functions simultaneously: they act as the delivery vehicle, the production factory, and the controlled release mechanism for interferon-β. This multi-functionality reduces the need for separate stabilization systems, formulations, and administration protocols that would otherwise be required.
Solution Approach 2:
The mutant Listeria bacteria self-regulate interferon-β production through their genetic modifications, automatically producing and releasing the interferon in a controlled manner without requiring external stabilization systems or complex delivery infrastructure.
Data Source
AI summary
Mutant Listeria bacteria that modulate interferon-β production are provided. The subject bacteria are characterized by having a mutation in a gene chosen from a TetR gene, a LadR gene, a VirR gene, a MarR gene a MdrL gene, a MdrT gene and a MdrM gene. The subject bacteria find use in a variety of applications, where representative applications of interest include, but are not limited to: (a) use of the subject bacteria as adjuvants; (b) use of the subject bacteria as delivery vectors for introducing macromolecules into a cell; (c) use of the subject bacteria as vaccines for eliciting or boosting a cellular immune response; etc.